Prostate Cancer Screening: Shared Decision-Making for Screening and Treatment.
Blackwelder, Russ; Chessman, Alexander.
; 46(1): 149-155, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30704655
Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.
Long-term survival of participants in the prostate cancer prevention trial.
5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
Prostate cancer in Brazil and Latin America: epidemiology and screening.
Las respuestas y conveniencia de la vigilancia activa en cáncer de próstata (en respuesta al comentario editorial del Dr. Sánchez Badajoz)
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.
BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.